Artivion (NYSE:AORT) Earns “Market Outperform” Rating from JMP Securities

Artivion (NYSE:AORT)‘s stock had its “market outperform” rating restated by equities research analysts at JMP Securities in a research report issued on Tuesday,Benzinga reports. They presently have a $33.00 price target on the stock. JMP Securities’ target price points to a potential upside of 10.29% from the company’s current price.

Other analysts have also issued reports about the stock. Needham & Company LLC restated a “buy” rating and set a $34.00 price target on shares of Artivion in a research report on Monday. Stifel Nicolaus increased their target price on Artivion from $28.00 to $30.00 and gave the company a “buy” rating in a report on Friday, September 13th. Finally, Oppenheimer lifted their price target on Artivion from $30.00 to $32.00 and gave the stock an “outperform” rating in a research note on Friday, November 8th. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Artivion presently has an average rating of “Buy” and a consensus price target of $31.80.

Artivion Trading Up 0.3 %

Shares of AORT opened at $29.92 on Tuesday. Artivion has a fifty-two week low of $16.48 and a fifty-two week high of $30.45. The firm has a market cap of $1.25 billion, a price-to-earnings ratio of -1,496.00 and a beta of 1.75. The firm has a 50 day moving average price of $27.58 and a 200-day moving average price of $26.14. The company has a debt-to-equity ratio of 0.71, a quick ratio of 1.33 and a current ratio of 1.88.

Insider Activity at Artivion

In related news, CAO Amy Horton sold 4,329 shares of the company’s stock in a transaction that occurred on Friday, December 6th. The stock was sold at an average price of $29.66, for a total value of $128,398.14. Following the sale, the chief accounting officer now owns 135,660 shares in the company, valued at $4,023,675.60. This represents a 3.09 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, VP Andrew M. Green sold 7,618 shares of Artivion stock in a transaction on Wednesday, December 4th. The shares were sold at an average price of $30.00, for a total value of $228,540.00. Following the transaction, the vice president now owns 33,503 shares of the company’s stock, valued at $1,005,090. The trade was a 18.53 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 24,377 shares of company stock worth $682,356 over the last quarter. Corporate insiders own 8.10% of the company’s stock.

Institutional Investors Weigh In On Artivion

A number of institutional investors have recently modified their holdings of AORT. Tidal Investments LLC raised its stake in shares of Artivion by 602.2% in the third quarter. Tidal Investments LLC now owns 157,002 shares of the company’s stock worth $4,179,000 after purchasing an additional 134,642 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its holdings in Artivion by 58.4% in the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 340,887 shares of the company’s stock worth $9,074,000 after buying an additional 125,668 shares in the last quarter. Perceptive Advisors LLC raised its position in Artivion by 4.7% in the 2nd quarter. Perceptive Advisors LLC now owns 2,793,703 shares of the company’s stock worth $71,658,000 after buying an additional 124,725 shares during the last quarter. Sio Capital Management LLC purchased a new stake in shares of Artivion during the 3rd quarter valued at about $3,226,000. Finally, Barclays PLC grew its stake in shares of Artivion by 346.3% in the third quarter. Barclays PLC now owns 70,877 shares of the company’s stock worth $1,888,000 after acquiring an additional 54,996 shares during the period. 86.37% of the stock is owned by hedge funds and other institutional investors.

Artivion Company Profile

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.